University of Texas MD Anderson: Pembrolizumab Shows Promise for Some Advanced, Hard-to-Treat Rare Cancers
March 21, 2020
March 21, 2020
HOUSTON, Texas, March 21 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
- Open-label Phase II study at MD Anderson reports on four cancer types
* * *
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat rare cancers. Study findings w . . .
* * *
- Open-label Phase II study at MD Anderson reports on four cancer types
* * *
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat rare cancers. Study findings w . . .